Skip to main content
2026 AANS Annual Scientific Meeting Main banner

    Adnan Siddiqui, MD PhD

    Vice-Chairman and Professor of Neurosurgery
    Department of Neurosurgery, University of Buffalo, SUNY

    Dr. Adnan H. Siddiqui, is Professor and Vice Chairman in the Department of Neurosurgery (UBNS) at the State University of New York at Buffalo’s Jacobs School of Medicine and Biomedical Sciences. He also serves as the Chief Executive Officer and Chief Medical Officer at the Jacobs Institute (JI) which is focused on entrepreneurship, development and education opportunities with partners in the medical technology industry including strategics, startups and individual inventors to advance the care of patients with vascular diseases.

    Dr. Siddiqui has special interest and expertise in the performance of complementary microsurgical, radiosurgical and endovascular techniques for the comprehensive management of cerebrovascular conditions. This spectrum of disease includes aneurysms and arteriovenous malformations, as well as dural, cavernous and spinal fistulae. He has special interests in endovascular management of acute ischemic stroke, as well as endovascular and microsurgical management of extracranial and intracranial vascular occlusive disease. Other clinical interests include endovascular management of intractable epistaxis, facial vascular malformations, head, neck, and brain tumor embolization and microsurgical resection of skull base tumors.

    Dr. Siddiqui has over 700 peer reviewed publications, more than 50 chapters, 52,000 citations and an H index of 98. He is particularly proud of representing Buffalo and the US at most major cerebrovascular conferences around the world with over 600 international presentations to date. He has designed, conducted and lead multiple major national and international clinical trials and currently serves as National and International PI for multiple major funded multi-site trials. These efforts have significantly contributed to the success of the department, which was ranked 7th in academic impact in North America by the Journal of Neurosurgery.

    Disclosure(s): , Q’Apel Medical, Inc., QAS.ai, Inc., Radical Catheter Technologies, Inc., ReNiva, Inc., Rist Neurovascular, Inc. (Purchased 2020 by Medtronic), Sense Diagnostics, Inc., Serenity Medical, Inc., Sim & Cure, Spinnaker Medical, Inc.,: Stock Options (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); 3N Endovascular, Adona Medical, Inc., Basecamp Vascular SAS, Bend IT Technologies, Ltd., BlinkTBI, Inc, Borvo Medical, Inc., CerebrovaKP, Code Zero Medical, Inc., Cognition Medical, Collavidence, Inc., Contego Medical, Inc., CVAID Ltd., CygnusMed, E8: Stock Options (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Abbott Laboratories, Acandis GmbH, Asahi Intecc Co. Ltd., Canon Medical Systems USA, Inc., Carotix Medical, LLC, CerebrovaKP, Cerenovus, Contego Medical, Inc., Cordis, Endostream Medical, Ltd (recently sold to Kaneka), FreeOx Biotech: Consultant (Ongoing); Endostream Medical, Ltd (Sold 2025 to Kaneka), FreeOx Biotech, SL, Galaxy Therapeutics, Inc., Hyperion Surgical, Inc., Imperative Care, Inc., InspireMD, Ltd., Instylla, Inc., IRRAS, AB,: Stock Options (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); Hyperfine Operations, Inc., Imperative Care , InspireMD, Ltd., Integra LifeSciences Corporation, IRRAS AB, Medtronic, Minnetronix Neuro, Inc., Medical Microinstruments, Inc., Peijia Medical, Penumbra, Inc. Perflow Medical, Ltd.,: Consultant (Ongoing); Jacobs Institute: Employee (Ongoing); Launch NY, Inc., Neurolutions, Inc., Neurovascular Diagnostics, Inc., NeXtGen Biologics, Peijia Medical, PerFlow Medical, Ltd., Physician X, LLC, Piraeus Medical, Inc., Prometheus Therapeutics, Inc., PUMA Venture Capital Fund I, LP: Stock Options (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); National PI/Steering Committees: Cerenovus EXCELLENT and ARISE II Trial; Medtronic ARTISSE IDE, SWIFT PRIME, VANTAGE, EMBOLISE and SWIFT DIRECT Trials; Terumo Neuro (formerly MicroVention) FRED Trial & CONFIDENCE Study; MUSC POSITIVE Trial;: Advisor (Ongoing), Board Member/Officer/Trustee (Ongoing), Consultant (Ongoing); National PI/Steering Committees: Penumbra 3D Separator Trial, COMPASS Trial, INVEST Trial, MIVI neuroscience EVAQ Trial; Rapid Medical SUCCESS Trial; InspireMD C-GUARDIANS IDE Pivotal Trial;: Advisor (Ongoing), Board Member/Officer/Trustee (Ongoing), Consultant (Ongoing); Patent No. US 11,464,528 B2, Date: October 11, 2022, CLOT RETRIEVAL SYSTEM FOR REMOVING OCCLUSIVE CLOT FROM A BLOOD VESSEL, Applicant and Assignee: Neuravi Limited (Galway), Role: Co-Inventor: Royalty Recipient (Ongoing); Piraeus Medical, Inc., Prometheus Therapeutics, Inc., Q’Apel Medical, Inc., Serenity Medical, Inc., Shockwave Medical, Inc., Sirtex Medical, Inc., Stryker Neurovascular., Synchron Australia Pty Ltd., Tegus Medical, GmbH,: Consultant (Ongoing); Stent’Up, Synchron, Inc., Tegus Medical, GmbH, T.G. Medical, Inc., Tulavi Therapeutics, Inc., Vastrax, LLC, Viseon, Inc., Viz.ai, Whisper Medical, Inc., Willow Medtech, Inc.: Stock Options (Ongoing), Stock Shareholder (excluding mutual funds) (Ongoing); T.G. Medical, Inc., Terumo Neuro (Formerly MicroVention), Unity Medical, Inc. Vastrax, LLC, Vesalio, Viz.ai, Inc., WL Gore: Consultant (Ongoing)

    Presentation(s):